HIV-1 Gag-specific CD8+ T-cell receptor (HIV-1 Gag TCR)

The HIV-1 Gag-specific CD8+ T-cell receptor is a specialized heterodimeric protein complex that recognizes specific viral peptides derived from the HIV-1 Gag polyprotein, including the p17 matrix and p24 capsid proteins, when presented by MHC class I molecules [PMID: 18931678]. These receptors are essential components of the adaptive immune system, allowing cytotoxic T lymphocytes to identify and destroy cells infected with HIV-1 [PMID: 22544354]. In the context of HIV infection, the Gag protein is a primary target for these receptors because it is highly expressed and contains relatively conserved epitopes like the SL9 peptide [PMID: 18414406]. Therapeutic interventions targeting these receptors include TCR-engineered T-cell (TCR-T) therapies and bispecific ImmTAV molecules, which are designed to enhance or redirect T-cell responses against the viral reservoir [PMID: 29167340]. These therapies work by facilitating the formation of an immunological synapse between the T cell and the infected cell, leading to targeted cell lysis [PMID: 23536651]. However, the high mutation rate of HIV-1 often leads to viral escape, where changes in the Gag sequence prevent TCR recognition [PMID: 26416954]. Additionally, these therapies are restricted by the patient's HLA type, requiring specific matching for the TCR to function correctly [PMID: 2735291]. Safety concerns associated with these treatments include potential off-target toxicity and the risk of cytokine release syndrome [PMID: 26416954].

Other names

HIV-1 p24-specific T-cell receptorHIV-1 p17-specific T-cell receptorGag-specific T-cell receptorHIV-specific CD8+ TCRHIV-1 Gag-specific CD8+ T-cell receptor

Recognition of HIV-1 Gag (p17/p24) peptides presented by MHC class I molecules, leading to the activation of cytotoxic T-cell responses and lysis of infected cells.